A peer-reviewed study of more than 46,000 older adults with type 2 diabetes found that patients who started GLP-1 receptor agonist drugs faced an 11 percent higher risk of fragility fractures compared to those prescribed other common diabetes medications. The findings, published in February 2026, arrive as separate research presented at the American Academy of Orthopaedic Surgeons meeting reported that osteoporosis risk was nearly 30 percent higher and tendon rupture risks were roughly 50 percent higher over five years among GLP-1 users. Together, these results are forcing a harder look at the musculoskeletal trade-offs of drugs like Ozempic and Wegovy, even as their metabolic benefits continue to drive record prescriptions.
Fracture Risk in Older Diabetic Patients
The central finding comes from a population-based retrospective cohort study conducted through the Clalit database in Israel, one of the largest integrated health systems in the world. Researchers tracked adults aged 65 or older with type 2 diabetes who began taking GLP-1 receptor agonists between 2018 and 2022, with follow-up extending through March 31, 2024. They compared outcomes against patients who instead started SGLT2 inhibitors or DPP-4 inhibitors, two other widely used classes of diabetes drugs.
The result was a hazard ratio of 1.11 for fragility fractures among GLP-1 users, meaning an 11 percent relative increase in risk. For a drug class increasingly prescribed to older adults because of its metabolic and cardiovascular benefits, even a modest fracture signal matters. Fragility fractures, which occur from low-energy impacts like a fall from standing height, are a leading cause of disability and death in people over 65. The study, detailed in a peer‑reviewed analysis of 46,177 participants, had enough statistical power to detect relatively small differences in outcomes.
Why might GLP-1 drugs weaken bones? The most plausible mechanism is indirect. These medications drive significant weight loss, and rapid weight reduction in older adults often accelerates loss of lean muscle mass and bone mineral density. Muscle and bone exist in a feedback loop: weaker muscles mean less mechanical loading on the skeleton, which in turn signals the body to reduce bone maintenance. For a 70-year-old already at elevated fracture risk due to age, diabetes-related neuropathy, or balance problems, shedding weight quickly could tip the balance toward injury.
Clinicians also note that appetite suppression from GLP-1 therapy may reduce intake of protein, calcium, and vitamin D if patients are not carefully counseled, further eroding bone health. In addition, people who lose substantial weight may experience changes in balance and gait as their center of gravity shifts, potentially increasing fall risk in the short term. None of these factors prove that GLP-1 molecules directly damage bone tissue, but they outline a biologically plausible pathway from rapid weight loss to more fractures.
FDA Adverse Event Data Adds a Second Signal
The Israeli cohort study did not emerge in isolation. A separate pharmacovigilance analysis drew on nearly two decades of data from the FDA Adverse Event Reporting System, covering reports filed between 2004 and 2022. That work identified disproportionate reporting of fracture-related adverse events for GLP-1 receptor agonists compared to several other glucose-lowering drugs.
FAERS data, however, comes with important caveats. Reports are voluntary and subject to underreporting, media influence, and duplicate entries. The database does not capture how many people in total used each drug, making it difficult to calculate true incidence rates. Nor does it systematically adjust for confounders such as age, baseline osteoporosis, or concurrent medications like steroids that can weaken bone.
Still, pharmacovigilance systems are designed as early warning tools, not definitive verdicts. The fact that fracture signals appear both in a controlled cohort and in a large national reporting database strengthens the case that the association is real rather than a statistical fluke tied to a single dataset. At the same time, the magnitude of risk in everyday practice remains uncertain, and both studies stop short of proving that GLP-1 drugs directly cause bone loss.
Tendon Injuries: A More Complicated Picture
Bone is only half the story. Research presented at the American Academy of Orthopaedic Surgeons meeting and summarized in a major news report found that tendon rupture risks were approximately 50 percent higher over five years among GLP-1 users, with osteoporosis risk nearly 30 percent higher. Clifford Rosen, an osteoporosis specialist, has cautioned that such findings should prompt closer monitoring of bone health in patients on these medications, particularly older adults and those with preexisting skeletal fragility.
Yet the orthopedic surgery literature tells a more nuanced story when the lens narrows to specific procedures. In one retrospective study of patients undergoing Achilles tendon repair, GLP-1 receptor agonist users actually had a lower rate of wound infection, with an odds ratio of 0.19 and a 95 percent confidence interval of 0.04 to 0.88. That translates to an 81 percent reduction in postoperative infections compared with matched controls. Other measured outcomes, including rerupture and thromboembolic events, did not differ significantly between groups, suggesting that GLP-1 exposure did not impair short-term tendon healing.
Rotator cuff repair patients show a similarly mixed pattern. In people with type 2 diabetes undergoing arthroscopic repair, prior semaglutide exposure was associated with lower retear risk and better functional scores at follow-up. Another analysis of shoulder surgery outcomes found that GLP-1 receptor agonist use was not linked to higher reoperation rates after rotator cuff repair, indicating no clear detriment to structural healing in that context.
These surgical series are smaller and more selective than the population-level data underpinning the AAOS presentations. They typically involve patients healthy enough to undergo elective procedures, treated in centers with standardized rehabilitation protocols, and followed closely by surgeons and physical therapists. That setting may blunt or even reverse some of the risks seen in broader community cohorts.
Why the Evidence Splits Along Body-Mass Lines
The apparent contradiction (higher tendon rupture risk in large population datasets but equal or better outcomes in specific orthopedic procedures) may reflect differences in who is taking GLP-1 drugs and how quickly they lose weight. In many of the newer weight-loss indications, patients start these medications with severe obesity and multiple comorbidities, then lose 15 to 20 percent of their body mass over a year. Rapid, substantial weight loss can decondition muscles and connective tissues if not paired with resistance training and adequate protein intake, potentially making tendons more vulnerable to spontaneous tears during everyday activity.
By contrast, patients in tendon repair studies are already under close orthopedic care. Their activity is structured, they receive physical therapy, and surgeons often emphasize gradual loading of the repaired tendon. GLP-1 therapy in that environment may improve glycemic control, reduce systemic inflammation, and help optimize body weight without the same degree of uncontrolled, rapid loss that might destabilize the musculoskeletal system.
Another factor is selection bias. People who undergo elective rotator cuff or Achilles surgery are a subset of GLP-1 users who have access to specialty care and who may be healthier overall than those represented in broad claims databases. They are also more likely to be monitored for nutritional status and bone health, which can mitigate some of the risks associated with aggressive weight reduction.
Implications for Patients and Clinicians
For patients, the emerging data do not mean that GLP-1 drugs are “too dangerous” to use. Instead, they underscore the need to treat these medications as powerful metabolic tools that require active management of side effects, not as cosmetic quick fixes. Older adults, particularly those with diabetes and preexisting osteoporosis or prior fractures, may benefit from baseline bone density testing, fall-risk assessment, and counseling on resistance exercise before or shortly after starting therapy.
Clinicians may also need to individualize dosing schedules. Slower titration, combined with nutritional support focused on adequate protein and micronutrients, could help preserve lean mass and bone density while still delivering meaningful weight loss and glycemic control. For patients with known tendon disease or prior ruptures, shared decision-making should include a discussion of the AAOS findings, balanced against the potential benefits of improved blood sugar and reduced cardiovascular risk.
Researchers, meanwhile, face a clear agenda. Prospective trials that incorporate bone mineral density scans, muscle mass measurements, and objective fall tracking would go a long way toward clarifying causality. Basic science work on how GLP-1 signaling interacts with bone-forming osteoblasts and bone-resorbing osteoclasts could reveal whether there are direct skeletal effects beyond weight loss and nutrition. Until those answers arrive, the best course is not to abandon GLP-1 drugs, but to use them with eyes open to their musculoskeletal trade-offs.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
